CRNX Crinetics Pharmaceuticals, Inc. Stock Quote

publish chart | save to portfolio | create alert

CRNX [NASD]

Crinetics Pharmaceuticals, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.39	Insider Own	4.49%	Shs Outstand	32.89M	Perf Week	7.16%
Market Cap	430.37M	Forward P/E	-	EPS next Y	-2.36	Insider Trans	-2.54%	Shs Float	27.79M	Perf Month	16.37%
Income	-66.70M	PEG	-	EPS next Q	-0.58	Inst Own	94.90%	Short Float	4.53%	Perf Quarter	-9.57%
Sales	0.40M	P/S	1075.92	EPS this Y	-86.10%	Inst Trans	-3.54%	Short Ratio	8.96	Perf Half Y	-9.06%
Book/sh	5.69	P/B	2.52	EPS next Y	-0.40%	ROA	-39.70%	Target Price	-	Perf Year	-26.62%
Cash/sh	6.23	P/C	2.30	EPS next 5Y	-	ROE	-43.40%	52W Range	10.63 - 26.67	Perf YTD	-42.77%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-46.00%	52W High	-46.16%	Beta	-
Dividend %	-	Quick Ratio	22.00	Sales past 5Y	-	Gross Margin	-	52W Low	35.09%	ATR	1.05
Employees	68	Current Ratio	22.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	55.17	Volatility	8.49% 7.65%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	6.60%	Profit Margin	-	Rel Volume	0.51	Prev Close	13.07
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	140.48K	Price	14.36
Recom	2.00	SMA20	10.13%	SMA50	0.31%	SMA200	-10.44%	Volume	71,485	Change	9.87%

Dec-23-19

Initiated

ROTH Capital

Buy

$37

Feb-14-19

Initiated

H.C. Wainwright

Buy

$35

Aug-13-18

Initiated

Piper Jaffray

Overweight

$40

Aug-13-18

Initiated

Leerink Partners

Outperform

$43

Aug-13-18

Initiated

JP Morgan

Neutral

$29

Nov-23-20 07:30AM	Crinetics Pharmaceuticals to Participate in December Investor Conferences GlobeNewswire -5.05%
Nov-16-20 07:30AM	Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology GlobeNewswire +5.51%
Nov-13-20 07:30AM	Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of Acromegaly GlobeNewswire
Nov-09-20 11:04AM	Should You Buy Crinetics Pharmaceuticals (CRNX) Ahead of Earnings? Zacks
Nov-06-20 08:31AM	Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire -6.01%
Oct-26-20 07:02AM	Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint GlobeNewswire -10.47%
Oct-14-20 10:25AM	Hedge Funds Are Piling Into Crinetics Pharmaceuticals, Inc. (CRNX) Insider Monkey
Sep-21-20 07:30AM	Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism GlobeNewswire
Sep-04-20 07:30AM	Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology GlobeNewswire
Sep-03-20 05:56PM	Crinetics Pharmaceuticals to Participate in September Investor Conferences GlobeNewswire -8.05%
07:30AM	Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors GlobeNewswire
Aug-07-20 07:30AM	Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire +8.83%
Jul-08-20 04:05PM	Crinetics Pharmaceuticals Receives Orphan Drug Designation for Paltusotine for the Treatment of Acromegaly GlobeNewswire
Jul-05-20 05:29PM	Should You Avoid Crinetics Pharmaceuticals, Inc. (CRNX)? Insider Monkey
Jun-30-20 07:02AM	Analysts' Revenue Estimates For Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Are Surging Higher Simply Wall St.
Jun-19-20 10:05AM	Crinetics Pharmaceuticals, Inc. (CRNX) Shares March Higher, Can It Continue? Zacks +16.32%
Jun-11-20 07:30AM	Crinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Clinical Trial for Paltusotine GlobeNewswire -8.89%
May-27-20 07:30AM	Crinetics Pharmaceuticals Appoints Adriana Cabré, MBA, as Vice President of Human Resources GlobeNewswire
May-14-20 08:51AM	Is Crinetics Pharmaceuticals (CRNX) Stock a Solid Choice Right Now? Zacks
May-08-20 09:01AM	Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire +5.01%
Apr-17-20 04:05PM	Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
12:00PM	Crinetics Pharmaceuticals, Inc. (CRNX) Upgraded to Buy: Here's What You Should Know Zacks
Apr-15-20 12:22AM	Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
Apr-14-20 04:05PM	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire +5.33%
Apr-07-20 07:55AM	The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation Benzinga -10.93%
Apr-06-20 04:30PM	Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate Update GlobeNewswire +10.99%
Mar-09-20 04:10PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update GlobeNewswire
Mar-04-20 12:30PM	Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-19-20 07:30AM	Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-28-20 07:11AM	Those Who Purchased Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares A Year Ago Have A 11% Loss To Show For It Simply Wall St.
Jan-08-20 07:30AM	Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference GlobeNewswire +5.61%
Dec-14-19 08:42PM	Hedge Funds Have Never Been This Bullish On Crinetics Pharmaceuticals, Inc. (CRNX) Insider Monkey
Nov-26-19 04:05PM	Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference GlobeNewswire
Nov-12-19 06:15PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:04PM	Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-05-19 10:31AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q3 Earnings Expected to Decline Zacks
Oct-30-19 10:57AM	Hedge Funds Have Never Been This Bullish On Crinetics Pharmaceuticals, Inc. (CRNX) Insider Monkey
Oct-28-19 11:31AM	We're Not Very Worried About Crinetics Pharmaceuticals's (NASDAQ:CRNX) Cash Burn Rate Simply Wall St.
Sep-25-19 07:30AM	Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference GlobeNewswire +6.32%
Sep-12-19 08:40AM	What Makes Crinetics Pharmaceuticals (CRNX) a Strong Sell? Zacks
Sep-03-19 04:05PM	Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference GlobeNewswire
Aug-13-19 06:15PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:14PM	Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-30-19 02:35PM	If You Had Bought Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock A Year Ago, You'd Be Sitting On A 14% Loss, Today Simply Wall St.
Jul-29-19 07:30AM	Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism GlobeNewswire -5.72%
Jul-16-19 09:05AM	Crinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors GlobeNewswire
May-21-19 07:30AM	Crinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors GlobeNewswire
May-13-19 04:11PM	Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
May-07-19 12:54PM	Heres What Hedge Funds Think About Crinetics Pharmaceuticals, Inc. (CRNX) Insider Monkey -5.67%
Mar-19-19 07:30AM	Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly GlobeNewswire
Mar-18-19 07:30AM	Crinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning GlobeNewswire
Mar-14-19 04:27PM	Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019 GlobeNewswire
Mar-13-19 04:05PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-21-19 07:30AM	Crinetics Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference GlobeNewswire -6.51%
Jan-16-19 10:16AM	Top 5 Small-Cap Winners And Losers, Week Of Jan. 7 Benzinga
Jan-08-19 12:50PM	At biotech's big event, a chance for execs to shape LGBTQ diversity on boards American City Business Journals
Jan-02-19 04:05PM	Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference GlobeNewswire
Nov-21-18 08:20AM	New Research Coverage Highlights Chuy's, Viveve Medical, ClearSign Combustion, WhiteHorse Finance, Crinetics Pharmaceuticals, and Boston Omaha Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire +9.88%
Nov-20-18 07:30AM	Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference GlobeNewswire
Nov-13-18 04:05PM	Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire +10.85%
Sep-26-18 04:05PM	Crinetics Pharmaceuticals to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology GlobeNewswire
Aug-30-18 04:07PM	Crinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Jul-20-18 04:05PM	Crinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-19-18 08:00AM	Todays Research Reports on Stocks to Watch: CTI BioPharma and Crinetics Pharmaceuticals ACCESSWIRE -7.55%
Jul-18-18 11:37AM	Crinetics Pharmaceuticals stock surges 24% in trading debut MarketWatch
07:27AM	Crinetics Pharmaceuticals prices IPO at $17 a share MarketWatch
Jul-17-18 06:55PM	Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Struthers Richard Scott	President & CEO	Jul 16	Sale	14.46	17,500	253,108	890,805	Jul 17 05:05 PM
Struthers Richard Scott	President & CEO	Jul 15	Sale	15.30	17,500	267,722	908,305	Jul 17 05:05 PM
WIERENGA WENDALL	Director	Apr 28	Option Exercise	0.73	25,329	18,490	99,846	Apr 29 05:01 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 17	Buy	14.00	1,071,428	14,999,992	3,659,381	Apr 20 08:30 AM
Vivo Capital VIII, LLC	10% Owner	Apr 17	Sale	15.40	84,598	1,302,809	298,625	Apr 17 06:38 PM
Vivo Capital VIII, LLC	10% Owner	Apr 16	Sale	15.20	30,190	458,888	308,890	Apr 17 06:38 PM
Vivo Capital VIII, LLC	10% Owner	Apr 15	Sale	15.50	215,810	3,345,055	312,553	Apr 17 06:38 PM
Vivo Capital VIII, LLC	10% Owner	Apr 07	Sale	14.20	6,115	86,833	338,738	Apr 07 07:27 PM
Vivo Capital VIII, LLC	10% Owner	Apr 03	Sale	13.80	300,000	4,140,000	339,480	Apr 07 07:27 PM
Vivo Capital VIII, LLC	10% Owner	Mar 09	Sale	19.50	528	10,296	168,165	Mar 11 05:12 PM
Vivo Capital VIII, LLC	10% Owner	Feb 10	Sale	21.40	7,555	161,677	168,298	Feb 11 08:00 PM
Vivo Capital VIII, LLC	10% Owner	Feb 07	Sale	22.00	5,905	129,910	174,202	Feb 11 08:00 PM
Vivo Capital VIII, LLC	10% Owner	Feb 04	Sale	22.80	13,460	306,888	178,816	Feb 06 07:22 PM
Vivo Capital VIII, LLC	10% Owner	Jan 31	Sale	21.70	5,400	117,180	189,335	Jan 31 08:00 PM
Vivo Capital VIII, LLC	10% Owner	Jan 30	Sale	22.10	7,600	167,960	193,555	Jan 31 08:00 PM
Vivo Capital VIII, LLC	10% Owner	Jan 29	Sale	22.20	13,920	309,024	199,495	Jan 31 08:00 PM
Fust Matthew K	Director	Dec 16	Option Exercise	1.91	3,500	6,685	16,036	Dec 18 06:32 PM
Fust Matthew K	Director	Dec 16	Sale	22.50	3,500	78,750	12,536	Dec 18 06:32 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience